Page 9 - COVID-19-Mortality-review-in-Malaysia-and-updates-on-clinical-management-of-COVID-19

1. Could you talk about drug therapy in COVID-19, namely about the withdrawn paper
on hydroxychloroquine (Lancet) and the usage of dexamethasone? Initially WHO has
advised us not to use steroids upfront. What is your comment on this?

2. In the previous webinar, it was mentioned that adolescents are more likely to have

Kawasaki Disease like illness (MIS-C). Do we see such characteristics among patients
older than 12 years old and young adults?

3. We know that in the later part of our national COVID-19 mortality committee, we
brought in forensic colleagues to help the committee. Dr.Faizah, can you share with

us, (clearly we are not doing post-mortem for every case), going forward, what is the
game plan for the Ministry of Health in terms of when do we do post-mortem among
COVID-19 cases who may passed away in the future?

4. What is your comment of the types of COVID-19 in South East Asia based on

Cambridge scientists?

5. Are there any COVID-19 cases in Malaysia or abroad that affect patients with

haemoglobinopathies such as thalassaemia or sickle cell?

6. What is the panellists’ view on using hydroxychloroquine (HCQ) at an early stage of
COVID-19 infection that might reduce the severity of COVID-19 patients? WHO

withdrew HCQ arm.

7. What is your opinion on WHO withdrawing the recruitment of patients for

hydroxychloroquine treatment in trial?

8. We hope there is no second surge of COVID-19, but as DG of Health has mentioned
many times, we are preparing for any possibilities. In terms of the clinical setup, will
there be a change in the way we set up our clinical services for COVID-19? As you

know there are some COVID-19 hospitals like Sungai Buloh Hospital, and we have
hybrid hospitals. Going forward, will there be change in how we deal with COVID-19

in the future, in terms of health care delivery?

9. We are all happy to see the data on COVID-19 patients’ recovery using
dexamethasone, as it is easy accessed to. Obviously, tocilizumab also has good data